Side effects of mandibular advancement splints for the treatment of snoring and obstructive sleep apnea: a systematic review

Olivia de Freitas Mendes Martins1,2, Cauby Maia Chaves Junior3, Rowdley Robert Pereira Rossi4, Paulo Afonso Cunali5, Cibele Dal-Fabbro6, Lia Bittencourt7

Introduction: Occlusal side effects or development of pain and/or functional impairment of the temporomandibular complex are potential reasons for poor compliance or abandonment of mandibular advancement splints treatment for snoring and obstructive sleep apnea. Objective: This study aimed at providing a comprehensive review evaluating the craniofacial side effects of oral appliance therapy for snoring and obstructive sleep apnea. Methods: An electronic search was systematically conducted in PubMed and Virtual Health Library from their inception until October 2016. Only Randomized Controlled Trials whose primary aim was to measure objectively identified side effects on craniofacial complex of a custom-made oral appliance for treating primary snoring or obstructive sleep apnea were included. Studied patients should be aged 20 or older. The risk of bias in the trials was assessed in accordance with the recommendations of The Cochrane Risk of Bias criteria. Results: A total of 62 full-text articles were assessed for eligibility. After the review process, only 6 met all the inclusion criteria. All studies were rated as having a high risk of bias. The most uniformly reported mandibular advancement splint side effects were predominantly of dental nature and included a decrease in overjet and overbite. The risk of developing pain and function impairment of the temporomandibular complex appeared limited with long-term mandibular advancement splint use. Conclusion: The limited available evidence suggests that mandibular advancement splint therapy for snoring and obstructive sleep apnea results in changes in craniofacial morphology that are predominantly dental in nature, specially on a long-term basis. Considering the chronic nature of obstructive sleep apnea and that oral appliance use might be a lifelong treatment, a thorough customized follow-up should therefore be undertaken to detect possible side effects on craniofacial complex. It is also important to provide adequate information to the patients regarding these possible changes, especially to those in whom larger occlusal changes are to be expected or in whom they are unfavorable. Long-term assessments of adverse effects of oral appliance therapy, with larger study samples and recruitment of homogenous patient population are still required.

Keywords: Obstructive sleep apnea. Adverse effects. Mandibular advancement splints. Systematic review.

1 Universidade Federal do Piauí, Curso de Especialização em Ortodontia (Teresina/PI, Brazil).
2 Centro Universitário UNINOVAFAPI, Curso de Especialização em Ortodontia (Teresina/PI, Brazil).
3 Universidade Federal do Ceará, Departamento de Ortodontia (Fortaleza/CE, Brazil).
4 Universidade Federal do Espírito Santo, Curso de Graduação em Odontologia (Vitória/ES, Brazil).
5 Universidade Federal do Paraná, Departamento de Odontologia (Curitiba/PR, Brazil).
6 Instituto do Sonho de São Paulo, Curso de Odontologia do Sonho (São Paulo/SP, Brazil).
7 Universidade Federal de São Paulo, Departamento de Psicobiologia (São Paulo/SP, Brazil).

How to cite: Martins OFM, Chaves Junior CM, Rossi RRP, Cunali PA, Dal-Fabbro C, Bittencourt L. Side effects of mandibular advancement splints for the treatment of snoring and obstructive sleep apnea: a systematic review. Dental Press J Orthod. 2018 July-Aug;23(4):45-54. DOI: https://doi.org/10.1590/2177-6709.23.4.045-054.oar

Submitted: January 26, 2017 – Revised and accepted: March 26, 2017

+ The authors report no commercial, proprietary or financial interest in the products or companies described in this article.

Contact address: Olivia de Freitas Mendes Martins
Av. Aviador Irapuã Rocha, 2336, Bairro de Fátima – Teresina/PI, Brasil
CEP: 64.048-232 – E-mail: oliviaortodontia@gmail.com
INTRODUCTION

Over the past decade, mandibular advancement splints (MAS) have been enthusiastically studied and considered as a simple, silent, bed partner-friendly, less invasive, tolerable, and efficacious choice for snoring and mild-to-moderate obstructive sleep apnea (OSA). The current literature increasingly supports MAS as an effective alternative to Continuous Positive Airway Pressure (CPAP) for patients with mild or moderate OSA. In a 2-year randomized trial of 103 patients, Doff et al compared subjective and objective treatment outcome of oral appliance (OA) therapy and CPAP in patients with OSA. They found that there was no statistical difference between treatments neither in the proportion of patients obtaining successful treatment (56% vs 60% in non-severe, and 50% vs 75% in severe for MAS and CPAP, respectively), nor in terms of subjective parameters for improvements in sleepiness, functional outcomes, and health perceptions (Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Medical Outcomes Study 36-item Short Form Health Survey [SF-36]). However, CPAP was more effective in lowering the apnea/hypopnea index and showed higher oxyhemoglobin saturation levels compared to OA therapy. It could be hypothesized that the suboptimal efficacy with MAS therapy is counteracted by the greater compliance with OA relative to CPAP, resulting in similar effectiveness of both treatments.

Based on their mechanism of action, OA for OSA can be grouped into two categories: tongue retaining appliances and mandibular advancement splints (MAS). Tongue retaining appliances are currently seldom used, mainly due to patient intolerance, being almost completely replaced by MAS. The quantity and quality of scientific literature supporting their use is far greater than for the other types of devices.

MAS are anchored to dentition and hold the mandible in a forward, vertically open position, pulling forward the tongue base and stretching pharyngeal soft tissues. Therefore, as these devices hold the mandible in an advanced and vertically opened position, they generate a continuously load to teeth and surrounding tissues by means of the traction forces exerted by the masticatory and mylohyoid muscles and soft tissue, which pull the mandible posteriorly into its habitual position, particularly during swallowing overnight. One force is labially directed to the mandibular incisors and the other is palatally directed to the maxillary incisors. It has been hypothesized that this may change the inclination and position of teeth, affect the position of the mandible and increase the loading to the craniomandibular complex.

In the initial period of MAS use, patients usually report tenderness of the teeth and jaws, gum irritation, excessive salivation or dry mouth. Nevertheless, these complaints are usually mild, acceptable and disappear with continued use, or they are easily resolved when addressed by the dentist. On a long-term basis, MAS therapy may result in objective adverse effects such as tooth movement, skeletal changes, and occlusal alteration.

Temporomandibular disorders (TMD) have been associated with the use of MAS. Doff et al assessed in patients with OSA the occurrence of TMD due to long-term use (2-year follow-up) of an OA compared to CPAP therapy. They found that OA therapy resulted in more pain-related TMD in the initial period of use compared with CPAP therapy, although generally it was not serious and it had a transient nature (tended to decrease afterwards). Moreover, mandibular function was not impaired in OSA patients using an OA or CPAP therapy. Therefore, authors suggest that the possible development of TMD or temporary pain of the temporomandibular complex is not a contra-indication for OA therapy in OSA patients.

Although the main reason for patients to stop wearing the OA is its ineffectiveness, potential reasons for poor compliance or discontinuation of MAS therapy are occlusal side effects or development pain and/or functional impairment of the temporomandibular complex. Furthermore, it is important a better understanding of the precise craniofacial effects of this therapy considering the chronic nature of OSA and that MAS use might be a lifelong treatment, aimed at helping dentists who treat sleep-disorder breathing to better understand the possible skeletal and dental/occlusal changes, as well the developing of pain and function impairment of the temporomandibular complex related to MAS therapy.

A 2004 systematic review investigated the safety of OA therapy in patients with OSA. Thirteen
studies were included for methodological appraisal, being one controlled clinical trial and twelve case series. Authors concluded that MAS therapy may result in adverse (although generally not serious) effects on the craniomandibular and craniofacial complex, which generally involve changes in dental occlusion. They also pointed out that controlled studies addressing co-morbidity of OA therapy were needed. Since this publication, recent articles have been published regarding the side effects of MAS as a treatment modality for OSA. Therefore, the aim of this study was to systematically review the available literature concerning the safety of MAS therapy for snoring and OSA.

METHODS

This systematic review followed The Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015).

Protocol and registration

Protocol and registration were not performed.

Eligibility criteria

The Population, Intervention, Comparison, Outcome and Study design (PICO) question format was used to formulate a clinical question and to elaborate inclusion criteria.

In adults (aged 20 or older) with OSA or snoring treated with MAS, what are the side effects on craniofacial complex measured objectively by clinical examination, cephalometric analyses and dental cast measurements?

» Population/patient: Adults (aged 20 or older) with OSA or snoring.

» Intervention: Treatment with a MAS.

» Comparison: Treatment versus control (CPAP, placebo or inactive appliance, uvulopalatopharyngoplasty) or before and after treatment.

» Outcome: Side effects on craniofacial complex measured objectively by clinical examination, cephalometric analyses and dental cast measurements.

» Study design: randomized clinical trials (RCTs).

Selection criteria

The inclusion criteria were: (1) studies whose primary aim was to measure objectively identified side effects on craniofacial complex of MAS for treating OSA; (2) studied patients diagnosed with OSA or primary snoring; (3) studied patients aged 20 or older; (4) intervention group treated with a custom-made MAS; (5) RCTs. The exclusion criteria were: (1) studies regarding only patient-perceived co-morbidity of this therapeutic modality (trials with nonclinical outcomes); (2) intervention group treated utilizing both mandibular protrusion and tongue retention. The search strategy was not limited to RCTs so that the reference lists of all articles obtained could be manually searched.

Information sources and search strategy

Search was performed on PubMed and the BVS (Virtual Health Library), that includes the databases LILACS, MEDLINE and Cochrane Library, from their inception until October 2016 (Fig 1). The search strategy for PubMed was conducted using medical subject headings (MeSH) and subheadings. Similar search terms were adopted for the other database. In addition, reference lists from relevant review articles and eligible studies was checked to identify any additional citations that might have been missed. No limits were applied to any of the search strategy.

Study selection

In the first step of the screening process, duplicated publications were excluded and two reviewers independently screened titles and abstracts, to identify full articles whose main purpose was to identify side effects on craniofacial complex of mandibular advancement for treating OSA. Any disagreements were resolved by a third reviewer. The same two authors evaluated the full text articles independently by applying the remaining inclusion criteria listed above. No limits were applied for language and foreign papers (not English) were translated.

Data items

For each selected trial, the following data were collected (Table 1): (1) first author and publication year; (2) methods (clinical examination, cephalometric analyses and dental cast measurements); (3) MAS type and amount of protrusion; (4) type and number of subjects; (5) control; (6) follow-up period; (7) MAS use (including nights/week and hours/night and study duration); and (8) side effects summary.
Table 1 - Summary of descriptive characteristics of included studies

| Author (year) | Method | MAS Type | MAS Protrusion | Subjects | Control | Follow-up period | MAS Use | Side effects summary |
|---------------|--------|----------|----------------|----------|---------|------------------|---------|----------------------|
| Doff et al.16 (2010) | Cephalometry | Thornton Adjustable Positioner (TAP®) | 79±20% of maximum protrusion | OSA | 31 | CPAP 2.3±0.2 year | > 6 nights/week | Overbite and overjet decreased; retroclination of the upper incisors and proclination of the lower incisors; lower and total anterior facial height increased significantly; no changes in skeletal variables were found |
| Doff et al.17 (2012) | Clinical measurements (RDC/TMD) and questionnaire | Thornton Adjustable Positioner (TAP®) | 76±25% of maximum protrusion | OSA | 51 | CPAP | 2 months, 1 year and 2 years | 6.7±0.6 nights/week | OA therapy results in more pain-related TMDs in the initial period of use, compared with CPAP therapy |
| Doff et al.17 (2013) | Dental plaster study models | Thornton Adjustable Positioner (TAP®) | 79±19% of maximum protrusion | OSA | 51 | CPAP | 2.3±0.2 year | 6.9±0.4 nights/week | Decreased overjet/overbite, antero-posterior change in the occlusion, decreased number of occlusal contact points in the posterior region |
| Ringqvist et al.14 (2003) | Cephalometry | Non-adjustable | 50% of maximum protrusion | OSA | 27 | Uvulopalatopharyngoplasty 4.1 year (4.0–4.2) | 6.1 nights/week | Changes in vertical positions of the maxillary incisors and the mandibular incisors, posterior rotation of the mandible; overjet and overbite did not change significantly |
| Robert-son et al.15 (2003) | Cephalometry | Non-adjustable | 75% of maximum protrusion | OSA/snoring | 100 | Pre-MAS therapy | 6, 12, 18, 24 and 30 months | > 5–6 hours/night 7 nights/week | Changes in face height, the position of the mandible, overjet, and overbite occurred as early as 6 months. Over-eruption of the maxillary first premolars and mandibular first molars and proclination of the mandibular incisors were not evident for at least 2 years. |
| Tegel-berg et al.16 (1999) | Clinical examination (Helkimo; Eichner index of occlusal support zones) | Non-adjustable | 50% of maximum protrusion | OSA | 37 | Uvulopalatopharyngoplasty | 1 year | 6 nights/week | Few adverse events in the stomatognathic system or other complications |

**Data collection process**

Data was extracted by two reviewers and then it was combined and compared for accuracy. Any disagreements were resolved by a third reviewer.

**Risk of bias in individual studies**

Two authors independently evaluated the risk of bias in the included studies following the recommendations of The Cochrane Risk of Bias criteria. Disagreements were resolved by a third reviewer.

**Data synthesis**

If the collected data was found to be adequate, a meta-analysis was considered.

**RESULTS**

**Study selection**

A flow diagram illustrating the number of citations identified, screened, and included in this review is outlined in Figure 1. A total of 518 articles were selected using the search strategy specified before. Of these, 55
were duplicated and were excluded. Six additional citations were identified from the references lists of relevant articles. Were discarded 407 articles after reviewing the titles and/or abstracts, remaining 62 articles of possible interest. Six studies finally met all the inclusion criteria and were included in this review.

**Study characteristics**

A summary of study characteristics of included trials is found in Table 1. Included articles were all in English language and most of them were conducted after the year 2000.

In most studies, only patients with mild to moderate OSA or asymptomatic snorers were included and it was used a non–adjustable OA that fixed the mandible in a predefined position at 50% or 75% of the maximum mandibular protrusion. The studies conducted by Doff et al compared possible adverse effects of a titratable OA with a CPAP control group in patients with mild to severe OSA. They used an adjustable OA and the mean mandibular protrusion during the follow-up period was 79 ± 20% of the maximal mandibular protrusion. They also studied the relationship between the occurrence of these effects and the degree of mandibular protrusion during OA therapy.

Two of the included articles studied possible side effects of MAS therapy on function and morphology of temporomandibular joint (TMJ) and masticatory muscles by clinical examination, including measurements of mandibular mobility, palpation of TMJ joints and masticatory muscles, and registrations of pain on mobility. In one of these two studies, clinical examination was quantified by the Clinical Dysfunction Score (CDS, Helkimo 1974), whereas the other used the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD), which evaluates TMD in a standardized manner. In three studies, dental/occlusal and skeletal adverse effects of MAS therapy were assessed by means of cephalometry, and in one study it was done by means of plaster cast measurements.

The duration of the included studies in this review was variable and ranged from 6 months to a mean follow-up of 4 years. Two study tried to determine the time course of adverse effects. Robertson et al took the review cephalogram at six month intervals (6, 12, 18, 24 or 30 months after placement of OA) to establish whether adverse effects were progressive with continuing treatment. Doff et al recorded TMD, pain intensity and disability and mandibular function impairment, at baseline, after 2 months, 1 year and 2 years of therapy.
Table 2 - Risk of bias assessment.

| Characteristic                        | Study                                      |
|--------------------------------------|--------------------------------------------|
|                                      | Doff et al, 2010                          |
|                                      | Doff et al, 2012                          |
|                                      | Doff et al, 2013                          |
| Sequence generation                  | Unclear                                   |
| (selection bias)                     | Unclear                                   |
| Allocation concealment               | Unclear                                   |
| (selection bias)                     | Unclear                                   |
| Blinding of participants and         | High: performance bias due to knowledge    |
| personnel (performance bias)         | of the allocated interventions by         |
|                                      | participants and personnel during the study|                                           |
| Blinding of outcome assessment       | Low: one blinded observer performed all    |
| (detection bias)                     | tracings                                  |
| Incomplete outcome data              | Low: reasons for withdrawals were both    |
| (attrition bias)                     | reported and balanced across groups       |
| Selective outcome reporting          | Low: pre-specified outcomes were reported  |
| (reporting bias)                     |                                           |
| Other sources of bias                | High: inter- and intraobserver reliability |
|                                      | measurements were not carried out          |
| Overall risk of bias                 | High                                       |

| Characteristic                        | Study                                      |
|--------------------------------------|--------------------------------------------|
|                                      | Ringqvist et al, 2003                      |
|                                      | Robertson et al, 2003                      |
|                                      | Tegelberg et al, 1999                     |
| Sequence generation                  | Unclear                                   |
| (selection bias)                     | Unclear                                   |
| Allocation concealment               | Unclear                                   |
| (selection bias)                     | Unclear                                   |
| Blinding of participants and         | High: performance bias due to knowledge    |
| personnel (performance bias)         | of the allocated interventions by         |
|                                      | participants and personnel during the study|                                           |
| Blinding of outcome assessment       | Unclear: unclear if outcome assessor was   |
| (detection bias)                     | blinded                                   |
| Incomplete outcome data              | High: large number of patients lost to     |
| (attrition bias)                     | follow up (33% in MAS group)              |
| Selective outcome reporting          | Low: pre-specified outcomes were reported  |
| (reporting bias)                     |                                           |
| Other sources of bias                | High: in the experimental (MAS) and control|
|                                      | (UPPP) groups, some patients (10% and 27%)|
|                                      | received both treatments                   |
| Overall risk of bias                 | High                                       |

Risk of bias within studies

Risk of bias assessment is shown in Table 2. All included studies were found to have high risk of bias potential. None of the trials described the method of randomization neither described allocation concealment, and they were all found to have high risk of bias.

Synthesis of results

Since the available collected information was found not to be adequate (high methodological heterogeneity among the studies that could be compared), a meta-analysis was not possible. The reported results are descriptive in nature.

Doff et al studied variations in the occurrence of TMDs and the risk of developing pain and function impairment of the temporomandibular complex in OSA patients treated with either a MAS or CPAP. They found that in the initial period after initiating OA or CPAP therapy (2 to 3 months), the occurrence of pain-related TMDs increases, being sub-
substantially higher (24%) in the OA group than in the CPAP group (6%). These findings correspond with the results of Tegelberg et al, which show that in the short-term MAS is likely to cause pain-related signs and symptoms of TMD, but these symptoms are characterized as mild and transient.

At the 12-month follow-up, Tegelberg et al observed that the mandibular movements, such as mouth opening, laterotrusion, and protrusion, did not change. The CDS was low before treatment and remained low during all observation period. However, authors emphasized that in the terminal phase of the study two patients developed a severe CDS and needed supplementary treatment with non-steroid anti-inflammatory drugs. This indicates that there may occur complaints regarding the masticatory muscles and the TMJs also when the mandible is moderately advanced.

Robertson et al randomly assigned one hundred adults with OSA and/or asymptomatic snoring to a group and reviewed 6, 12, 18, 24 or 30 months after placement of a non-adjustable MAS. There were 20 subjects in each group. Craniofacial changes were measured on lateral cephalometric radiographs taken at the initial and review appointments. The differences between each subject’s review and initial film were used to determine the skeletal, dental and occlusal changes. There was considerable variation both within and between groups when the changes over time were examined. Reductions in overbite (OB) and overjet (OJ), 0.61 and 0.87 mm, respectively, were evident at 6 months.

Studies included in this review has shown that MAS use appear to be not detrimental to TMJ health and function in OSA patients on a long-term basis. Doff et al assessed the occurrence of TMD as result of long-term use of a MAS compared to CPAP in OSA patients and found that the occurrence of TMD-related pain increases in the initial period of OA therapy but tends to return to baseline values during a 2-year follow-up. They also showed that OA therapy does not cause pain-induced limitations of the temporomandibular complex and no differences were found in mandibular function impairment during the 2-year follow-up between OA and CPAP therapy.

Nearly all studies included in this review that investigated dental changes have found a significant change in the relationship between maxillary and mandibular incisors, with decreased OB and OJ. Reductions in OB and OJ ranged from 1.0 to 1.2 mm and 1.06 to 1.7 mm, respectively, after long-term appliance use. It is generally hypothesized that these changes can be attributed to a labially directed force to the mandibular incisors and a palatally directed force to the maxillary incisors during OA therapy while the mandible attempts to return to a more dorsal position. On the other hand, Ringqvist et al did not observe significant changes in these measurements after 4 years of OA therapy.

Doff et al observed a more mesial molar and canine relationship after long-term use of MAS. The consequence is a Class III tendency, with a shift in molar and cuspid occlusion from Class I to Class III or a shift from Class II to Class I or III.

A significant retroclination of the maxillary incisors and proclination of the mandibular incisors were observed in the majority of studies that investigated dental changes. Doff et al found a retroclination of $-2.0 \pm 2.8^\circ$ for the upper incisors and a proclination of $3.7 \pm 5.4^\circ$ for the lower incisors.

The bite tends to open in the (pre)molar region, resulting in a decrease in the number of occlusal contact points in the (pre)molar region. A tendency towards the development of a (bi)lateral crossbite in the (pre) molar region has been found after long-term OA use.

Downward rotation of the mandible and increasing in lower facial height has been observed following long-term MAS therapy.

**DISCUSSION**

In this systematic review, the available evidence about the craniofacial side effects of MAS therapy for snoring and OSA was investigated. Since quantity and quality of scientific literature supporting MAS use is far greater than for other types of devices, this review was limited to the side effects of this kind of appliances for the treatment of OSA.

Following selection process, only a limited number of articles was found and most of them with methodological restrictions. It is important to note that non-adjustable appliances that fix the mandible in a predefined position at 50–75% of the maximum mandibular protrusion were used in three studies, and their results may not be fully comparable with those in which totally adjustable appliances were used. Furthermore, those trials included only patients with non-apneic snoring
or mild to moderate OSA, while the others\textsuperscript{10,16,17} included
moderate to severe OSA, and protrusive positions of the
mandible over 75% of the patient’s maximum mandibu-
lar protrusion were applied in some patients. Severe OSA
patients may need more pronounced protrusive positions
of the mandible in order to experience sufficient benefit
from MAS therapy.\textsuperscript{16}

For didactic purposes, side effects of MAS treat-
ment were divided into two parts: (1) short/medium-
term effects of MAS treatment (follow-up ≤ 1 year); and
(2) long-term side effects of MAS treatment (follow-up
> 1 year). Within each category, side effects were di-
vided into three sections: (1) TMDs; (2) dental/occlusal
changes; and (3) skeletal changes.

Short/medium term side effects

Studies with a follow-up up to 1-year (≤ 1 year) were
included in this section.

Temporomandibular disorders

Studies included in this review have shown that in
the short-term MAS are likely to cause pain-related
signs and symptoms of TMD, but these symptoms are
characterized as mild and transient.\textsuperscript{10,15} Two possible ex-
planation for this finding have been presented: (1) the
strain in the muscles of the temporomandibular com-
plex or the capsular ligament of the TMJ when protrud-
ing the mandible during sleep; and (2) an increase in
occlusal vertical dimension while wearing OA.\textsuperscript{10}

Dental/occlusal changes

Only one study included in this review addressed
dental/occlusal changes on a short-term basis (follow-
up ≤ 1 year). Robertson et al\textsuperscript{13} observed that reduc-
tions in OB and OJ (0.61 and 0.87mm, respectively)
and reductions in maxillary arch length were evident
as early as after 6 months of treatment. These changes
were attributed to the appliance acting directly on the
incisors, with significant retroclination of the maxil-
lary incisors and proclination of the mandibular inci-
sors. Increased pressure from the lips due to the altered
mandibular posture might also play a part.\textsuperscript{13}

Skeletal changes

Robertson et al\textsuperscript{13} observed that skeletal changes oc-
curred soon after the onset of treatment (6 months).
Small but statistically significant increases in face height
were accompanied by a significant downward position
of the mandible. At 12-month follow-up, only down-
ward displacement of the mandibular symphysis was
found. However, the authors point out that, based in
the findings from this study, the so-called skeletal and
mandibular positional changes can be mainly attributed
to appliance-induced dental changes.

Long-term side effects

This section included side effects observed in studies
with a follow up of more than 1 year (> 1 year). They
were also grouped into the same sections as the short-
term/medium effects (TMD, dental/occlusal changes,
and skeletal changes).

Temporomandibular disorders

Studies included in this review\textsuperscript{10,15} have shown that
MAS use seems to be not detrimental to TMJ health
and function in OSA patients on a long-term basis.
Although in the short-term MAS are likely to cause pain-
related signs and symptoms of TMD, all pain-related
TMD had decreased after 1 year\textsuperscript{10,15} and 2 year\textsuperscript{10} of using
MAS. Doff et al\textsuperscript{10} hypothesized that the temporoman-
dibular complex has adaptive capacities to the unnatural
protrusive position during sleep while wearing an OA,
and thus the device could have a therapeutic effect in
patients with TMD.

Dental/occlusal changes

Most studies included in this review have found a
significant change in the relationship between maxil-
lary and mandibular incisors, with reductions in OB
and OJ.\textsuperscript{13,14,16,17} It is generally hypothesized that these
changes can be attributed to a labially directed force
to the mandibular incisors and a palatally directed
force to the maxillary incisors during OA therapy
while the mandible attempts to return to a more dor-
sal position.\textsuperscript{17} On the other hand, Ringqvist et al\textsuperscript{14}
did not observe significant changes at anterior teeth
after 4 years of OA therapy. Differences in appliance
design and amount of protrusion would explain these
findings. Ringqvist et al\textsuperscript{14} used an OA in which both
frontal parts of upper and lower dental arches were
not covered by acrylicate, possibly resulting in less
forces applied to the upper and lower incisors. An-
other explanation could be the degree of mandibu-
lar protrusion of 50% while wearing the OA\textsuperscript{14} versus
protrusive positions of the mandible over 75% of the patient’s maximum mandibular protrusion applied in some patients in the former studies.16,17

Robertson et al13 observed a significant positive correlation between the amount of anterior opening by the MAS and changes in OB at 24 and 30 months follow-up. Therefore, it was postulated that the changes in OB could be lessened by keeping the bite opening to a minimum. Furthermore, by using linear regression analysis, Doff et al16 observed an association between the mean amount of mandibular protrusion during the follow-up period (2.3±0.2 years) and the decrease in OB. This result confirms the finding of a previous cephalometric study conducted in the same patient population.10 Findings of these two trials suggest that it is important to use a sagittally adjustable OA (stepwise advancement) that allow for individual titration. That approach lowers the risk of mandibular advancement beyond the optimal degree of protrusion.

A tendency towards the development of a (bi)lateral crossbite in the (pre)molar region has been found after long-term OA use.17 It could be explained by the fact that, with a mesial shift in occlusion, the broader part of the mandibular dental arch will occlude with the narrower part of the maxillary dental arch.17

The bite tends to open in the (pre)molar region, resulting in a significant decrease in the number of occlusal contact areas.17 It occurs probably because of the incisal guidance phenomenon (decrease in OJ and OB). However, it has been suggested that the open bite tendency tend to stabilize over time because of the development of a new occlusal equilibrium.17

It is important to emphasize that not all occlusal changes resulting from long-term OA therapy should be interpreted as unfavourable.9 In other words, some effects can lead to beneficial orthodontic changes in specific cases. For example, decreasing in overjet effects and the tendency towards a mesioclusion (more mesial molar and canine) are favorable for Class II division 1 patients. Therefore, effects of OAs may be considered on an individual basis. Additionally, patient perceptions to occlusal changes do not correlate with objective measurements.8

Skeletal changes

Downward rotation of the mandible and increases in lower facial height have been observed following long-term MAS therapy.13,14,16 Ringqvist et al14 hypothesized that it would have been an effect of the anchorage of the MAS at the molars (well-fitting Adams clasps), with extrusion of the molars as patients attempted to open their mouth during sleep. Doff et al16 also believe that these skeletal changes were predominantly the result of dental changes, such as proclination of the mandibular incisors, retroclination of the maxillary incisors, and molar extrusion.

Since treatment of OSA with MAS is probably a long-lasting process, a thorough customized follow-up should therefore be undertaken to detect possible side effects on craniofacial complex.

LIMITATIONS

Some methodological limitations of this review should be mentioned. Electronic search was performed in only two databases and grey literature was not searched. In an attempt to avoid as much selection bias as possible, the search strategy was not limited to RCTs, reference lists from relevant review articles and eligible studies were manually searched, and no limits were applied to any of the search strategy. Also, due to methodological and clinical heterogeneity among the studies that could be compared, the synthesis of results was considered unreliable.

CONCLUSIONS

The limited available evidence suggests that MAS therapy for snoring and OSA results in changes in craniofacial morphology that are predominantly dental in nature, particularly on a long-term basis. It is important to provide adequate information to the patients regarding these possible changes, especially to those in whom larger occlusal changes are to be expected or in whom they are unfavorable. Long-term assessments of adverse effects of MAS therapy with larger study samples and recruitment of homogenous patient population are still required.

Authors contribution

Conception or design of the study: OFMM, CMCJ, RRPR, PAC, CDF, LB. Data acquisition, analysis or interpretation: OFMM, CMCJ, RRPR. Writing the article: OFMM, CMCJ, RRPR. Critical revision of the article: OFMM, CMCJ, RRPR, PAC, CDF, LB. Final approval of the article: OFMM, CMCJ, RRPR, PAC, CDF, LB.
REFERENCES

1. Chen H, Lowe AA. Updates in oral appliance therapy for snoring and obstructive sleep apnea. Sleep Breath. 2013 May;17(2):473-86.
2. Doff MHJ, Hoekema A, Wijkstra PJ, Van der Hoeven JH, Huddleston Slater JJR, De Bont LGM et al. Oral appliance versus continuous positive airway pressure in obstructive sleep apnea syndrome: a 2-year follow-up. Sleep. 2013 Sept;36(9):1289-96.
3. Hoffstein V. Review of oral appliances for treatment of sleep-disordered breathing. Sleep Breath. 2013 Mar;11(1):1-22.
4. Ghazal A, Jonas IE, Rose EC. Dental side effects of mandibular advancement appliances— a 2-year follow-up. J Orofac Orthop. 2008 Nov;69(6):437-47.
5. Hoekema A, Stegenga B, De Bont LG. Efficacy and comorbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review. Crit Rev Oral Biol Med. 2004 June;15(3):137-55.
6. Cohen-Levy J, Pételle B, Pinguet J, Limerat E, Fleury B. Forces created by mandibular advancement devices in OSAS patients: a pilot study during sleep. Sleep Breath. 2013 May;17(2):781-9.
7. Marklund M. Predictors of long-term orthodontic side effects from mandibular advancement devices in patients with snoring and obstructive sleep apnea. Am J Orthod Dentofacial Orthop. 2006 Feb;129(2):214-21.
8. Rose EC, Staats R, Virchow C Jr, Jonas IE. Occlusal and skeletal effects of an oral appliance in the treatment of obstructive sleep apnea. Chest. 2002 Sept;122 (3):871-7.
9. Almeida FR, Lowe AA, Otsuka R, Fastlicht S, Farbod M, Tsuiki S. Long-term sequelae of oral appliance therapy in obstructive sleep apnea patients: Part I. Cephalometric analysis. Am J Orthod Dentofacial Orthop. 2006 Feb;129(2):205-13.
10. Doff MHJ, Veldhuis SK, Hoekema A, Slater JJ, Wijkstra PJ, De Bont LG, et al. Long-term oral appliance therapy in obstructive sleep apnea syndrome: a controlled study on temporomandibular side effects. Clin Oral Investig. 2012 June;16(3):689-97.
11. Moher D, Shamseer L, Clarke, M, Ghersi, D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4:1. Doi: 10.1186/2046-4053-4-1.
12. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane Coll. 2011. Available from: www.handbook.cochrane.org.
13. Robertson C, Herbison P, Harkness M. Dental and occlusal changes during mandibular advancement splint therapy in sleep disordered patients. Eur J Orthod. 2003 Aug;25(4):371-6.
14. Ringqvist M, Walker-Engström ML, Tegelberg A, Ringqvist I. Dental and skeletal changes after 4 years of obstructive sleep apnea treatment with a mandibular advancement device: a prospective, randomized study. Am J Orthod Dentofacial Orthop. 2003 July;124(1):53-60.
15. Tegelberg A, Wilhelmsson B, Walker-Engstrom M, Ringqvist M, Andersson L, Krekmanov L, et al. Effects and adverse events of a dental appliance for treatment of obstructive sleep apnea. Swed Dent J. 1999;23(4):117-26.
16. Doff MHJ, Hoekema A, Pruim GJ, Huddleston Slater JJR, Stegenga B. Long-term oral-appliance therapy in obstructive sleep apnea: a cephalometric study of craniofacial changes. J Dent. 2010 Dec;38(12):1010-8.
17. Doff MHJ, Finnema KJ, Hoekema A, Wijkstra, PJ, Bont LGM, Stegenga M. Long-term oral appliance therapy in obstructive sleep apnea syndrome: a controlled study on dental side effects. Clin Oral Investig. 2013 Mar;17(2):475-82.